Article
The FDA has approved Visudyne (verteporfinfor injection) therapy for the treatment of predominantly classic subfovealchoroidal neovascularization (CNV) caused by pathologic myopia and presumedocular histoplasmosis.
FDA issues Complete Response Letter to Aldeyra Therapeutics for resubmitted New Drug Application of reproxalap
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Myopia onset predicted by accelerated eye changes a year in advance
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Economic burden of late-stage age-related macular degeneration
Zeiss Medical Technology gains NMPA approval for ILM-Blue in China